Loading current stock analysis…
Loading current stock analysis…
India
As of 12 Oct 2026, 03:30 pm
Sun Pharma's board is scheduled to consider a Non-Convertible Debenture (NCD) issue of up to ₹15,000 crore on October 12, 2026. The debentures are proposed to be issued through private placement in one or more tranches.
On October 6, 2026, Sun Pharma established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai through a $2.5 million endowment. Additionally, the company has informed the exchange about a board meeting on October 12, 2026, to consider fundraising, and has published notices regarding a postal ballot/e-voting process in October 2026.
As of October 12, 2026, Sun Pharma's recent returns include +5.3% over the last year, +2.3% year-to-date, and -4.3% over the last month. The stock has shown annualized volatility of +20.5% and a current drawdown of -12.0%, with a maximum drawdown of -17.3%.
The nearest technical resistance levels for Sun Pharma are at ₹1762.6 (0.15% above current price), ₹1765.64 (0.32% above current price), ₹1774.2 (0.81% above current price), and ₹1788.4 (1.61% above current price). Key support levels are identified at ₹1748.4 (0.66% below current price), ₹1736.8 (1.32% below current price), ₹1726.12 (1.93% below current price), and ₹1722.6 (2.12% below current price).
As of 12 Oct 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹15,299.88 crore | ₹14,611.79 crore | PEAK₹15,520.54 crore | ₹14,478.31 crore | ₹13,851.40 crore |
| Profit Before Tax | ₹4,098.81 crore | ₹3,551.34 crore | PEAK₹4,227.16 crore | ₹4,167.61 crore | ₹3,172.77 crore |
| Finance Costs | ₹99.67 crore | ₹85.89 crore | ₹78.36 crore | PEAK₹99.86 crore | ₹74.80 crore |
| Exceptional Items Before Tax | -₹204.09 crore | PEAK₹0.0 | -₹489.48 crore | PEAK₹0.0 | -₹818 crore |
| Comprehensive Income For The Period | ₹4,410.38 crore | ₹4,213.03 crore | ₹4,161.69 crore | PEAK₹4,540.38 crore | ₹2,420.29 crore |
| Other Comprehensive Income | PEAK₹1,509.15 crore | ₹1,503.37 crore | ₹780.52 crore | ₹1,415.43 crore | ₹127.42 crore |
Revenue from operations was ₹15,299.88 crore, compared to ₹13,851.40 crore in the same quarter last year, an increase of 10.5%. Sequentially, revenue rose 4.7% from ₹14,611.79 crore in the preceding quarter (Q4 FY2025-26). Over the past five quarters, revenue peaked in Q3 FY2025-26 at ₹15,520.54 crore, declined in Q4, and recovered in the current quarter.
Major operating costs for the quarter included cost of materials consumed (₹2,026.28 crore), employee benefit expense (₹3,227.23 crore), and depreciation, depletion, and amortisation (₹738.72 crore). Together, these three items accounted for 39.1% of revenue. Finance costs added another ₹99.67 crore.
Basic and diluted earnings per share from continuing operations were ₹12.10, up from ₹9.50 a year ago, a 27.4% increase. The EPS figures for continuing and discontinued operations are identical, indicating no material impact from discontinued operations on per-share earnings. The equality of basic and diluted EPS also points to the absence of dilutive equity instruments.
Disclosed bulk and block transactions involving Sun Pharmaceutical Industries, shown for the latest 90 days.
Exchange disclosures and regulatory announcements for Sun Pharmaceutical Industries.
Sun Pharmaceutical Industries Limited's Board of Directors approved the issuance of non-convertible debentures (NCDs) on a private placement basis for an aggregate amount not exceeding INR 10,000 Crore. Concurrently, Mr. Gautam Doshi resigned as a Non-Executive, Independent Director with effect from 12 October 2026 due to personal reasons. The Board authorized its Finance Committee to determine tranche-specific terms and conditions within the approved framework.
Sun Pharmaceutical Industries’ board approved privately placed listed, rated, unsecured, redeemable non-convertible debentures in one or more tranches for an aggregate amount not exceeding INR 10,000 crore; the Finance Committee will set tranche-specific terms within the approved framework, with disclosures to follow upon issuance or allotment. Effective 12 October 2026, Non-Executive Independent Director Gautam Doshi resigned for personal reasons and ceased to hold Board committee positions; he confirmed no other material reasons for his resignation.
Gautam Doshi resigned as Sun Pharmaceutical Industries Limited’s Non-Executive Independent Director, effective October 12, 2026. The company reported that the resignation was for personal reasons and confirmed there was no material reason other than those provided in his resignation letter; no monetary amount or affected operating business area was disclosed. The filing also lists his directorships at Aashni Ecommerce Private Limited, Connect Capital Private Limited, and Capricon Realty Private Limited.
Sun Pharmaceutical Industries Limited has informed the Exchange about Resignation of Director/KMP/SMP |SUBJECT: Resignation of Director/KMP/SMP
Other business matters |Meeting Date: 12-Oct-2026
Board Meeting Intimation |Meeting Date: 12-Oct-2026
Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 12-Oct-2026 to consider Fund raising. |SUBJECT: Board Meeting Intimation
On October 6, 2026, Sun Pharmaceutical Industries Limited established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai through a $2.5 million endowment to fund academic leadership in perpetuity. Mark G. Lebwohl, MD, was installed as the inaugural professor during a ceremony held that day at Hatch Auditorium at The Mount Sinai Hospital in New York. The initiative supports research, education, and mentorship within the Kimberly and Eric J. Waldman Department of Dermatology, with Ahmad Naim, MD, Senior Vice President and Chief Medical Officer of North America, citing the commitment to fostering future leaders in the field.
Recent market and company developments associated with Sun Pharmaceutical Industries.
Indian pharmaceutical industry, innovative medicines India, clinical trials India, pharma regulatory challenges, Sun Pharma Organon acquisition, Glenmark AbbVie deal, pharma R&D investment, Indian pharma global expansion, IFQM Symposium 2026, pharma market access India
Sun Pharma’s board will consider an NCD issue of up to ₹15,000 crore on October 12. The debentures are proposed to be issued through private placement in one or more tranches.
Indian pharmaceutical leaders emphasize the need for investment in innovation to transition from generics to innovative products. They highlight the importance of regulatory reforms and a strong ecosystem for research and development. Industry executives mention that the next decade will be critical for this transformation and urge companies to capitalize on scientific talent. Government initiatives are acknowledged as supportive in this endeavor for global competitiveness.
stock
Indian corporations are making bold strides abroad, with Essar establishing a massive $15 billion steel complex in Iowa. Notable companies such as Tata Motors and Reliance are also venturing into international markets across diverse sectors. However, the declining investments from mid-level Indian firms raise concerns about potential impacts on employment and economic growth at home. The ongoing debate is whether Globalisation 2.
Sun Pharma is planning to raise about Rs 10,000 crore through rupee-denominated bonds to partly refinance a bridge loan used for its Organon acquisition, according to Reuters. The drugmaker is expected to issue two-, three- and four-year bonds as Indian companies increasingly turn to domestic debt amid high US borrowing costs and expectations of an RBI rate hike.
pharma stocks
With Indian equities under pressure from high crude prices and rising bond yields, experts recommend a cautious investment approach. Focus on accumulating high-quality stocks while monitoring key factors. Tailored strategies emphasize technical analysis and sector strength amidst ongoing volatility.
Comprehensive Section Breakdown for Sun Pharmaceutical Industries
Strategic Vision: Develops, manufactures, and commercializes pharmaceutical products globally.
• Vertically integrated manufacturing operations
• Diverse portfolio of generic, branded generic, and specialty pharmaceutical products
• In-house API production capabilities
• Global research and development centers
Sun Pharmaceutical Industries Limited reported revenue of ₹15,299.88 crore for the quarter ended 30 June 2026, up 10.5% from the same quarter last year. Profit before tax increased 29.2% to ₹4,098.81 crore, partly driven by a reduction in exceptional charges from ₹818 crore to ₹204 crore. Excluding exceptional items, underlying profit before tax grew 7.8%, slower than revenue. Comprehensive income rose sharply due to a large other comprehensive income component.
Profit before tax (PBT) increased 29.2% year-on-year to ₹4,098.81 crore from ₹3,172.77 crore. The prior-year quarter included an exceptional charge of ₹818 crore, while the current quarter had a smaller exceptional charge of ₹204.09 crore. Adjusting for these items, PBT before exceptional items was ₹4,302.90 crore versus ₹3,990.77 crore a year ago, a growth of 7.8% — below the revenue growth rate of 10.5%. This indicates that underlying profitability did not expand as much as the headline PBT figure suggests.
Finance costs rose to ₹99.67 crore from ₹74.80 crore a year ago, a 33.3% increase, and also increased sequentially from ₹85.89 crore in Q4. Other income for the quarter was ₹723.62 crore.
Comprehensive income for the period was ₹4,410.38 crore, up 82.2% from ₹2,420.29 crore in the same quarter last year. This large increase was primarily due to a surge in other comprehensive income (OCI), which rose from ₹127.42 crore to ₹1,509.15 crore. OCI in the current quarter was nearly flat compared to the preceding quarter (₹1,503.37 crore). Net profit for the period was ₹2,901.23 crore, implying an effective tax rate of about 29.0% on the reported PBT.
Sun Pharma’s June 2026 quarter delivered revenue growth of 10.5% year-on-year, but the 29% increase in profit before tax was significantly influenced by a reduction in exceptional charges. Underlying profit growth, excluding exceptional items, was slower than revenue growth. Comprehensive income was boosted by a large other comprehensive income component, which has been elevated in recent quarters. The company had no dilutive securities, and discontinued operations had no material effect on per-share earnings.
Category: Manufacturing
Manufactures finished oral solid dosages, injectables, liquids, and ointments marketed across cardiovascular, neuropsychiatry, gastroenterology, and anti-infective therapeutic segments.
Category: Manufacturing
Develops and commercializes proprietary, clinically differentiated medicines primarily in dermatology, ophthalmology, and oncology.
Key Products & Services: tildrakizumab • cyclosporine ophthalmic solution
Category: Manufacturing
Produces bulk chemical substances, including peptides, steroids, and cytotoxic active ingredients for captive use and export to global pharmaceutical manufacturers.
Core Thesis: A vertically integrated model balances high-volume generic production with specialized, research-intensive clinical portfolios.
• Hybrid Brand Strategy: The company bridges branded generics in emerging markets with innovative specialty medicines in regulated markets, using generics cash flow to fund specialty product development. • API Sourcing & Backward Integration: In-house API manufacturing secures raw chemical inputs for finished dosage formulations, managing costs and supply chain risks. • R&D and Product Pipeline Integration: Global research centers develop complex generic delivery mechanisms and process chemistry, transferring technology to manufacturing sites. • Therapeutic Focus (Specialty Franchise): The innovative business concentrates on dermatology, ophthalmology, and oncology, with dedicated sales representatives detailing these brands.
Reported ownership for FY2027-Q1 as of 2026-06-30.